Dallas, Texas, United States, October 21, 2026
Nanoscope Therapeutics, Inc. has announced the publication of preclinical research demonstrating targeted, sustained visual responses using an investigational optical coherence tomography (OCT)-guided, non-viral gene delivery platform. Published in Frontiers in Pharmacology, the study evaluated the company’s nano-enhanced optical delivery (NOD) technology for delivering multi-characteristic opsin (MCO)-encoding genes into selected regions of the degenerating retina. The research addresses a major challenge in retinal gene therapy: delivering therapeutic genetic material precisely to surviving retinal cells after light-sensing photoreceptors have been lost. In mouse models of retinal degeneration, a single treatment produced measurable retinal and brain responses to light that remained detectable for up to 52 weeks. Researchers also reported no detectable treatment-related toxicity in the evaluated retinal structure, cell viability, intraocular pressure or electrophysiological function. These findings support further investigation of localized, non-viral gene delivery as a potential approach to treating retinal degenerative disorders. The research remains preclinical, and the NOD platform has not been evaluated in humans. Additional studies will be necessary to establish its safety, effectiveness and suitability for clinical use.
OCT-Guided Technology Enables Targeted Retinal Gene Delivery
Nanoscope’s nano-enhanced optical delivery (NOD) platform combines functionalized plasmonic gold nanorods with low-power near-infrared laser light to facilitate the entry of genetic material into selected retinal cells. The technology uses OCT imaging to visualize retinal structures and guide delivery toward specific regions affected by degeneration. OCT is an established imaging technique that generates detailed cross-sectional images of the retina, helping researchers identify target areas. In the experimental platform, near-infrared laser energy transiently increases cell membrane permeability, enabling plasmid DNA carrying the therapeutic gene to enter targeted cells. The study investigated delivery of the company’s multi-characteristic opsin (MCO) gene, designed to make surviving inner retinal neurons responsive to light after photoreceptor loss. Unlike conventional viral-vector approaches, the NOD platform does not rely on a viral capsid to transport the genetic payload. This could potentially provide flexibility for delivering larger genetic constructs, including certain gene-editing tools. However, the ability to deliver larger payloads and the platform’s potential advantages require further investigation. The researchers assessed gene expression, retinal structure, electrophysiological responses and potential effects on non-target tissues to evaluate the approach’s performance and preliminary safety.
Mouse Studies Show Visual Responses Lasting 52 Weeks
The study evaluated NOD-mediated gene delivery in rd1 mice, an experimental model characterized by rapid and severe photoreceptor degeneration. Following treatment, researchers observed MCO expression in inner retinal cells within the targeted regions, without detectable disruption of retinal structure or changes in retinal thickness. Electrophysiological assessments showed stronger light-evoked retinal responses and visually evoked cortical responses in treated animals compared with untreated controls. Importantly, these responses remained detectable throughout the 52-week observation period, suggesting sustained biological activity following a single treatment. Researchers also evaluated the platform in a separate focal laser-injury model designed to reproduce selected features of geographic atrophy, a form of advanced dry age-related macular degeneration. In this model, localized delivery restored measurable retinal responses in the injured region within one week. Biodistribution analysis at 12 months found that vector DNA levels in evaluated non-target tissues were comparable to control levels. These results provide encouraging evidence of targeted delivery and long-lasting functional responses in animal models. Nevertheless, electrophysiological signals are not equivalent to demonstrated improvements in visual acuity, reading ability or everyday vision in humans. The results cannot yet establish whether the technology will restore useful vision in patients.
Advertisement
Nanoscope Advances Research for Retinal Degenerative Diseases
Nanoscope Therapeutics develops investigational therapies for people experiencing vision loss caused by retinal degeneration, including retinitis pigmentosa (RP), Stargardt disease and geographic atrophy. These conditions involve the progressive loss of photoreceptors and can lead to substantial visual impairment. The company’s broader MCO research program seeks to restore light sensitivity by enabling surviving retinal neurons to respond to light, potentially without requiring a treatment tailored to each patient’s specific genetic mutation. Separately, Nanoscope’s investigational MCO-010 therapy has advanced into clinical development for retinal diseases; its regulatory status and clinical evidence should not be confused with the preclinical NOD delivery platform described in this publication. The latest study establishes an early scientific foundation for combining retinal imaging with localized non-viral gene delivery. Further work will need to assess reproducibility, dose selection, long-term safety, manufacturing consistency and the feasibility of translating the approach into human studies. The publication represents a research milestone, not an approved treatment or proof of human vision restoration. If future investigations confirm its safety and effectiveness, OCT-guided NOD could offer a potential platform for targeted genetic therapies addressing retinal degeneration.
Source: Nanoscope Therapeutics press release
